Engineered t cells take on deadly brain tumors in new trial
NCT ID NCT03170141
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This early-stage trial tests a new treatment for glioblastoma, an aggressive brain cancer. It uses a patient's own immune cells that are genetically modified to better recognize and attack the tumor. The study enrolls 30 people with recurrent glioblastoma and aims to check the treatment's safety and how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.